Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lyell Immunopharma (LYEL) Cash from Financing Activities (2020 - 2025)

Historic Cash from Financing Activities for Lyell Immunopharma (LYEL) over the last 6 years, with Q3 2025 value amounting to $50.0 million.

  • Lyell Immunopharma's Cash from Financing Activities changed N/A to $50.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $50.6 million, marking a year-over-year increase of 297166.26%. This contributed to the annual value of $1.3 million for FY2024, which is 2392.43% down from last year.
  • As of Q3 2025, Lyell Immunopharma's Cash from Financing Activities stood at $50.0 million.
  • In the past 5 years, Lyell Immunopharma's Cash from Financing Activities ranged from a high of $393.5 million in Q2 2021 and a low of -$531000.0 during Q3 2021
  • In the last 5 years, Lyell Immunopharma's Cash from Financing Activities had a median value of $862500.0 in 2022 and averaged $25.8 million.
  • The largest annual percentage gain for Lyell Immunopharma's Cash from Financing Activities in the last 5 years was 208905.33% (2021), contrasted with its biggest fall of 161714.29% (2021).
  • Over the past 5 years, Lyell Immunopharma's Cash from Financing Activities (Quarter) stood at $7.4 million in 2021, then tumbled by 88.34% to $863000.0 in 2022, then fell by 12.05% to $759000.0 in 2023, then plummeted by 42.42% to $437000.0 in 2024, then surged by 11341.65% to $50.0 million in 2025.
  • Its Cash from Financing Activities was $50.0 million in Q3 2025, compared to $183000.0 in Q2 2025 and $1000.0 in Q1 2025.